Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Key Highlights
- ➤Roivant Social Ventures announced a six-figure legacy donation to No Patient Left Behind
- ➤RSV is closing its institutional work after six years of healthcare-access programming
- ➤No Patient Left Behind will continue RSV’s mission to improve drug affordability and access
Expert Statements
Lindsay Androksi, Founder and Board President of Roivant Social Ventures
“I am immensely proud of RSV's work incubating and investing in early-stage companies and launching and expanding educational and fellowship opportunities for future equity-minded industry leaders. We also co-founded groups working to bring new therapies to underserved patient populations, such as the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group, and are excited to see those organizations continue their important work. I am grateful to Roivant Sciences for enthusiastically supporting the launch of Roivant Social Ventures six years ago and our projects since that time. I can think of no better organization to carry on our legacy than NPLB.”
Priscilla VanderVeer, Executive Director of No Patient Left Behind
“Roivant Social Ventures has opened doors for people who need help accessing medicines. We’re honored by this donation, and will continue their legacy as we work to improve affordability while preserving the innovation ecosystem we all rely on.”
NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing medical innovation, through a six-figure legacy donation.
RSV is a 501(c)3 public charity and social impact organization that partners with innovative companies, institutes, and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered. The organization launched with the vision of a world where every person is born with the right and ability to access medicine and medical care, regardless of their geographic location, wealth, or insurance status. In striving for this goal, RSV spent the last six years building out programing to increase access to therapeutics for underserved people, while working to embed these principles throughout the biotechnology and healthcare industries.
Get started
Create a free account to read the full story.